PGx for VTE Risk Assessment
Venous thromboembolism (VTE) is a venous return disorder caused by abnormal clotting of blood in the veins. These include deep vein thrombosis (DVT) and pulmonary embolism (PE).VTE is a complex polygene-environmental disorder, about 60% of which is attributed to genetic factors (genetic polymorphisms) that determine the susceptibility of different individuals to VTE and that this susceptibility persists throughout life.Venous thrombosis risk assessment genetic testing
PGx for Anticoagulant Drug
Scheme introductionBy detecting genes related to anticoagulants, analyze the gene types and gene defects contained in patients and whether their expression function is normal, assist doctors to develop individualized drug treatment plans for patients, and achieve predictable and accurate personalized medication, in order to achieve high efficiency and low toxicity treatment purposes.Genetic polymorphism of CYP2C19 enzyme causes significant differences in enzyme activity among different individua
PGx for Hypertension Drugs
Gene detection of antihypertensive drugs
Pharmacogenomics (PGx) Product Catalogue
MerlinBiomedical Drug gene monitoring catalog
